
Please try another search
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It’s lead product candidate is rezatapopt, an orally available small molecule that potently and selectively correct p53 misfolding caused by p53 mutation, Y220C, while sparing wild-type p53. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.
Name | Age | Since | Title |
---|---|---|---|
Charles M. Baum | 67 | 2021 | Independent Director & Chair of Clinical Advisory Board |
Kirsten Flowers | 49 | 2022 | Independent Director |
Carol G. Gallagher | 60 | 2022 | Independent Director |
Charles L. Sawyers | 66 | - | Member of Clinical Advisory Board |
Richard A. Heyman | 68 | 2020 | Independent Chairman of the Board of Directors & Member of Scientific Advisory Board |
Scott W. Lowe | - | 2024 | Chairman of Scientific Advisory Board |
David H. Mack | 63 | 2013 | Co-Founder, CEO, President & Director |
Laurie D. Stelzer | 57 | 2020 | Independent Director |
Guillermina Lozano | - | 2021 | Member of Scientific Advisory Board |
Arnold J. Levine | 85 | 2013 | Co-Founder, Independent Director & Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review